Navigation Links
MiStent SES Shown to be Unique in Clinical Setting
Date:10/28/2013

uated using angiography, IVUS and OCT at three time points: four, six and eight months. The primary efficacy endpoint was in-stent late lumen loss. Safety was assessed by incidence of MACE and presence of strut coverage with tissue within the treated artery at each time point. William Wijns, M.D., Ph.D., Cardiovascular Center, Aalst, Belgium and John Ormiston, M.B.Ch.B., Mercy Angiography Unit, Auckland, New Zealand are co-principal investigators for this trial.

The DESSOLVE II CE (Conformite Europeenne) Mark trial is a randomized, multi-center study of patients with documented stable or unstable angina pectoris. The primary endpoint is superiority of the MiStent SES in minimizing in-stent late lumen loss at nine months, compared to Medtronic's Endeavor® Sprint DES, as measured by an independent angiography core laboratory in de novo coronary lesions in vessels ranging in diameter from 2.5 to 3.5 mm and amenable to treatment with a maximum 30 mm length stent. The DESSOLVE II study completed enrollment of 184 patients in July 2011. Data analysis confirms that DESSOLVE II met all study objectives, demonstrated a competitive in-stent late lumen loss, and achieved strong signal of safety.

About Micell Technologies Inc.

Micell Technologies is a biomedical company that is enhancing the performance of cardiovascular medical devices with innovative drug-delivery systems. Its unique surface and polymer modification technologies enable Micell to precisely and consistently control drug elution and polymer exposure duration, creating the potential for a therapeutic solution to coronary artery disease without the long-term safety concerns of currently available drug-eluting stents. Micell is also developing a drug-coated balloon for vascular interventions. Visit us at www.micell.com.

Caution Regarding Forward-Loo
'/>"/>

SOURCE Micell Technologies
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micell Technologies Receives CE Mark Approval for MiStent SES
2. Micell Technologies Announces Development and Distribution Agreement to Bring MiStent SES to China
3. Early Coronary Artery Healing Advantage of OrbusNeichs Combo Dual Therapy Stent™ Compared to the TAXUS® Stent Shown in Two Clinical Trial Subgroup Analyses
4. Pycnogenol® (French Maritime Pine Bark Extract) Shown To Improve Endothelial Function And Reduce Oxidative Stress In New Clinical Trial
5. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
6. Daily Cocoa Flavanol Consumption Shown to Improve Cognitive Function in Older Adults
7. Israeli Innovation Shown to Demonstrate Reduction in Headaches and Neck Pain
8. Natural Tree Extract (Larch Arabinogalactan) Shown to Have Statistically Significant Effect in Protecting Immune Health
9. EarlySense System Implementation Shown to Reduce Falls, Decrease Transfers to Hospitals and Increase the Quality of Care for Elderly in Multi-Center Nursing Home Study
10. Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate
11. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  Tandem Diabetes ... device company and manufacturer of the t:slim® and ... entered into non-exclusive Development Agreements with Dexcom, Inc. ... insulin pumps with the Dexcom G5 and G6 ... Tandem,s next generation pump platform with Dexcom,s future ...
(Date:7/30/2015)... THOUSAND OAKS, Calif., July 30, 2015  Amgen ... for the second quarter of 2015. Key results ... versus the second quarter of 2014 to $5,370 ... primarily by Enbrel ® (etanercept), Prolia ® ... (carfilzomib) and XGEVA ® (denosumab). Unfavorable ...
(Date:7/30/2015)... N.J. , July 30, 2015 Eisai ... in the United States , European ... FDA, EMA and MHLW, respectively) for eribulin, for the ... who have received prior chemotherapy for advanced or metastatic ... on data from a pivotal global Phase 3 clinical ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... HILL, N.C., Feb. 27, 2012  Cempra, Inc. (Nasdaq: ... developing antibiotics to meet critical medical needs in the ... underwriters of its recent initial public offering have exercised ... shares of common stock.  The closing of the over‑allotment ...
... Johnson thought the $912mm charge in the 4th quarter of ... litigation; however the recent 4th quarter charge of $2.9bil partly ... 3 times last year,s amount.  This has ... litigation could top Avandia as the top "class action" litigation ...
Cached Medicine Technology:Cempra, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Cempra, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares 3CNJ Enterprises: DePuy ASR Hip Implant Recall Large Contributor to Johnson & Johnson's $2.9 Bil Charge for 4th Quarter 2011 2
(Date:7/31/2015)... ... ... According to the article published July 27 on My News LA, a fire ... by the city’s fire department before it caused major damage throughout the building. The article ... and it was a fire alarm system that tipped off fire fighters so they could ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Well-known for its ... offering wedding cakes with custom designs, making life just a little bit ... designed wedding cakes for each customer who orders one. , The bakery provides a ...
(Date:7/31/2015)... ... July 31, 2015 , ... Cosmetic Town has proven itself ... various plastic surgery procedures including, but not limited to, abdominoplasty, blepharoplasty, rhinoplasty and ... Botox and fillers. , Staying up to date with the latest cosmetic ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... geared to patients and family members, medical professionals, and researchers, covering a variety ... The conference is a collaborative effort between the Mesothelioma Applied Research Foundation and ...
(Date:7/31/2015)... ... ... Creating one of the most modern fertility centers in the Middle East, ... the boundaries of fertility medicine. , As the leading gynecology and fertility hospital ... affordable treatments, unending hope, and high fertility success rates — all contributing to its ...
Breaking Medicine News(10 mins):Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 3
... as it is commonly known, is generally referred to any ... of an individual. // Stress, as we all know, has ... and the old alike. ,Although it has been ... implications, especially on health, are many. During stress, an important ...
... cancer. According to the statistics it was found that the ... the Brazilian government plans to test the new Gardasil vaccine ... government plans to release the vaccine in the market. Brazilian ... Brazilian women against the human Papilloma virus (HPV). ...
... the combination of HIV and tuberculosis were evidenced from 2003, ... ,Western Cape tops for the highest TB rate in Africa. ... cause of mortality in South Africa. ,Thabo Mbeki, ... the dreaded conditions behind it which put in action after ...
... has ruled that the pharmaceutical companies and the state were ... , and has awarded damages to nine people who had ... were prescribed fibrinogen as well as other coagulants, between 1981 ... that has closed down now. ,The Osaka District ...
... increase rise in the obesity and diabetic rate among ... their life expectancy. //This has also pressurized the already ... from cancer declined about 14 % and also from ... that average life expectancy for Australians, at 78 years ...
... of Abhishek, all of five years and seven months but with ... adult man. ,The boy's face gives the impression of ... have developed like that of an adult. ,Abhishek, ... of Choti Balia, a village in Begusarai district, about 130 km ...
Cached Medicine News:Health News:Doctors Confused by the Manly Characteristics of a Five-year-old Boy 2
... The ABSOLOK EXTRA Ligating Clip Applier ... ligating clips. The instrument and clips are ... of ligation of tubular structures where an ... optimizes visibility of the clip at the ...
... stapler places one staple each time the instrument ... skin and are then formed, thus holding the ... two sizes: wide (having a clip span of ... clip span of 9.9 mm before closure). The ...
The Auto Suture™ SIGNET™ staplers place one staple each time the instrument handles are squeezed. The staples first penetrate the skin and are then formed, thus holding the tissue togethe...
... PREMIUM skin stapler places one ... handle is squeezed. The staple ... is then formed, thus holding ... different sizes of staples, each ...
Medicine Products: